First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study.

Buteau 2025 · Buteau James P, Kostos Louise, Jackson Price A, et al. · The Lancet. Oncology · 2025